Why the study?
A dual-axis lipid framework combining ApoB with the LDL-C/TC ratio characterizes atherogenic particle burden and cholesterol composition, but whether associations of these phenotypes with ASCVD differ by inflammatory status remained uncertain.
Does the association of dual-axis lipid phenotypes (defined by ApoB and LDL-C/TC ratio) with incident ASCVD differ by inflammatory status (hsCRP and GlycA) in adults without baseline cardiovascular disease not on lipid-lowering therapy?
Does the association of dual-axis lipid phenotypes (defined by ApoB and LDL-C/TC ratio) with incident ASCVD differ by inflammatory status (hsCRP and GlycA) in adults without baseline cardiovascular disease not on lipid-lowering therapy?
In over 284,000 primary prevention UK Biobank participants, dual-axis lipid phenotypes (combining ApoB and LDL-C/TC) and elevated inflammatory markers independently predicted higher absolute ASCVD risk, though the lipid phenotype overlapped substantially with non-HDL-C and showed inconsistent relative risk modification by inflammatory status.
Answers are grounded in this paper and cite their sources.
Dual-elevated lipid phenotypes may aid ASCVD risk stratification across inflammation levels; leaves open whether targeting them improves outcomes beyond non-HDL cholesterol.
A dual-axis lipid framework combining apolipoprotein B (ApoB) with the low-density lipoprotein cholesterol to total cholesterol ratio (LDL-C/TC) characterizes atherogenic particle burden and cholesterol composition. Whether associations of these phenotypes with atherosclerotic cardiovascular disease (ASCVD) differ by inflammatory status remains uncertain. We analyzed 284,251 UK Biobank participants without cardiovascular disease who were not receiving lipid-lowering therapy at baseline. Phenotypes were defined by ApoB ( < 90 vs ≥90 mg/dL) and LDL-C/TC ( < 0.60 vs ≥0.60). Associations with incident ASCVD were evaluated using multivariable Cox models across high-sensitivity C-reactive protein (hsCRP) and glycoprotein acetyls (GlycA) strata. Exploratory analyses assessed combined lipid and inflammatory marker burden among participants with Systematic Coronary Risk Evaluation 2 (SCORE2) < 10%. During a median 14-year follow-up, 13,535 ASCVD events occurred. Compared with the dual-normal phenotype, adjusted hazard ratios were 1.08 (95% confidence interval [CI], 1.00–1.15) for low-ApoB/high-ratio, 0.98 (0.90–1.06) for high-ApoB/low-ratio, and 1.23 (1.17–1.29) for dual-elevated phenotypes. Phenotype associations differed by binary hsCRP status (P for interaction = 0.010): for the dual-elevated phenotype, the adjusted hazard ratio was 1.28 (1.20–1.37) with hsCRP <2 mg/L and 1.09 (1.01–1.18) with hsCRP ≥2 mg/L. Nevertheless, ASCVD incidence was higher with hsCRP ≥2 mg/L than with hsCRP <2 mg/L (4.6 vs 3.0 per 1,000 person-years). Effect modification was not reproduced using three clinical hsCRP categories (P for interaction = 0.480) or GlycA strata (P for interaction = 0.940). Among participants with SCORE2 < 10%, the 10-year absolute risk difference versus those with no elevated markers increased from 0.46% with one elevated marker to 2.01% with four. The dual-elevated association persisted after adjustment for high-density lipoprotein cholesterol but was largely attenuated after adjustment for non–high-density lipoprotein cholesterol. Dual-axis lipid phenotypes were associated with heterogeneous ASCVD risk. Higher inflammatory burden consistently marked greater absolute risk, whereas modification of relative lipid-associated risk was limited to the binary hsCRP definition and was not reproduced with alternative inflammatory classifications. The phenotype associations overlapped substantially with conventional lipid components, and exploratory combined-marker analyses identified residual absolute-risk heterogeneity without establishing incremental predictive or clinical utility.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: